Abstract
Data from large studies show that theophylline is still being prescribed for up to 35% of patients with chronic obstructive pulmonary disease (COPD) (1), although the currently valid guidelines define it as a third-line medication. The role of theophylline in the treatment of asthma and COPD has changed drastically in recent decades, primarily due to the introduction of new classes of substances—the long-acting bronchodilators (beta-2 sympathomimetics and anticholinergics) and inhaled steroids—with high efficacy and a more favorable side effect profile.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
